Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mónica Martínez-Cengotitabengoa is active.

Publication


Featured researches published by Mónica Martínez-Cengotitabengoa.


BMC Psychiatry | 2011

Reduced antioxidant defense in early onset first-episode psychosis: a case-control study

Juan Antonio Micó; M.O. Rojas-Corrales; Juan Gibert-Rahola; Mara Parellada; Dolores Moreno; David Fraguas; Montserrat Graell; Javier Gil; Jon Irazusta; Josefina Castro-Fornieles; Cesar A. Soutullo; Celso Arango; Soraya Otero; Ana Navarro; Inmaculada Baeza; Mónica Martínez-Cengotitabengoa; Ana González-Pinto

BackgroundOur objective is to determine the activity of the antioxidant defense system at admission in patients with early onset first psychotic episodes compared with a control group.MethodsTotal antioxidant status (TAS) and lipid peroxidation (LOOH) were determined in plasma. Enzyme activities and total glutathione levels were determined in erythrocytes in 102 children and adolescents with a first psychotic episode and 98 healthy controls.ResultsA decrease in antioxidant defense was found in patients, measured as decreased TAS and glutathione levels. Lipid damage (LOOH) and glutathione peroxidase activity was higher in patients than controls. Our study shows a decrease in the antioxidant defense system in early onset first episode psychotic patients.ConclusionsGlutathione deficit seems to be implicated in psychosis, and may be an important indirect biomarker of oxidative stress in early-onset schizophrenia. Oxidative damage is present in these patients, and may contribute to its pathophysiology.


Schizophrenia Bulletin | 2014

Pro-/Anti-inflammatory Dysregulation in Patients With First Episode of Psychosis: Toward an Integrative Inflammatory Hypothesis of Schizophrenia

Borja García-Bueno; Miquel Bioque; Karina S. MacDowell; M. Fe Barcones; Mónica Martínez-Cengotitabengoa; Laura Pina-Camacho; Roberto Rodriguez-Jimenez; Pilar A. Saiz; Carmen Castro; Amalia Lafuente; Javier Santabárbara; Ana González-Pinto; Mara Parellada; Gabriel Rubio; M. Paz García-Portilla; Juan Antonio Micó; Miguel Bernardo; Juan C. Leza

BACKGROUND Schizophrenia is a chronic syndrome of unknown etiology, predominantly defined by signs of psychosis. The onset of the disorder occurs typically in late adolescence or early adulthood. Efforts to study pathophysiological mechanisms in early stages of the disease are crucial in order to prompt intervention. METHODS Case-control study of first-episode psychotic (FEP) patients and matched controls. We recruited 117 patients during the first year after their FEP according to the DSM-IV criteria and recruited 106 gender-, race-, and age-matched controls between September 2010 and June 2011. RESULTS Biochemical studies carried out in peripheral mononuclear blood cells (PMBC) and plasma evidence a significant increase in intracellular components of a main proinflammatory pathway, along with a significant decrease in the anti-inflammatory ones. Multivariate logistic regression analyses identified the expression of inducible isoforms of nitric oxide synthase and cyclooxygenase in PMBC and homocysteine plasma levels as the most reliable potential risk factors and the inhibitor of the inflammatory transcription factor NFκB, IκBα, and the anti-inflammatory prostaglandin 15d-PGJ2 as potential protection factors. DISCUSSION Taken as a whole, the results of this study indicate robust phenotypical differences at the cellular machinery level in PMBC of patients with FEP. Although more scientific evidence is needed, the determination of multiple components of pro- and anti-inflammatory cellular pathways including the activity of nuclear receptors has interesting potential as biological markers and potential risk/protective factors for FEP. Due to its soluble nature, a notable finding in this study is that the anti-inflammatory mediator 15d-PGJ2 might be used as plasmatic biomarker for first episodes of psychosis.


Schizophrenia Research | 2012

Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes

Mónica Martínez-Cengotitabengoa; Karina S. MacDowell; Juan C. Leza; Juan Antonio Micó; Miryam Fernández; Enrique Echevarría; Julio Sanjuán; Julian Elorza; Ana González-Pinto

INTRODUCTION This study measures the levels of various markers of oxidative stress and inflammation in blood samples from first-episode psychosis (FEP) patients, and examines the association between these peripheral biomarkers and cognitive performance at 6 months after treatment. METHODS Twenty-eight FEP patients and 28 healthy controls (matched by age, sex and educational level) had blood samples taken at admission for assessment of total antioxidant status, superoxide dismutase (SOD), total glutathione (GSH), catalase (CAT), glutathione peroxidase, lipid peroxidation, nitrites and the chemokine monocyte chemoattractant protein-1 (MCP-1). A battery of cognitive tests was also applied to the healthy controls and those FEP patients who were in remission at 6 months after the acute episode. RESULTS FEP patients had significantly lower levels of total antioxidant status, catalase and glutathione peroxidase, compared with the healthy controls. Regression analyses found that MCP-1 levels were negatively associated with learning and memory (verbal and working), nitrite levels were negatively associated with executive function, and glutathione levels were positively associated with executive function. CONCLUSION Our results suggest an association between certain peripheral markers of oxidative stress and inflammation and specific aspects of cognitive functioning in FEP patients. Further studies on the association between MCP-1 and cognition are warranted.


Schizophrenia Research | 2012

Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study

David Fraguas; Ana González-Pinto; Juan Antonio Micó; Santiago Reig; Mara Parellada; Mónica Martínez-Cengotitabengoa; Josefina Castro-Fornieles; Marta Rapado-Castro; I. Baeza; Joost Janssen; Manuel Desco; Juan C. Leza; Celso Arango

Progressive loss of cortical gray matter (GM), as measured by magnetic resonance imaging, has been described early in the course of first-episode psychosis. This study aims to assess the relationship between oxidative balance and progression of cortical GM changes in a multicenter sample of first-episode early-onset psychosis (EOP) patients from baseline to two-year follow-up. A total of 48 patients (13 females, mean age 15.9±1.5 years) and 56 age- and gender-matched healthy controls (19 females, 15.3±1.5 years) were assessed. Magnetic resonance imaging (MRI) scans performed both at the time of the first psychotic episode and 2 years later were used for volumetric measurements of left and right gray matter regions (frontal, parietal, and temporal lobes) and total sulcal cerebrospinal fluid (CSF). Total glutathione (GSH) blood levels were determined at baseline. In patients, after controlling for possible confounding variables, lower baseline GSH levels were significantly associated with greater volume decrease in left frontal (B=0.034, 95% confidence interval (CI): 0.011 to 0.056, r=0.620, p=0.006), parietal (B=0.039, 95% CI: 0.020 to 0.059, r=0.739, p=0.001), temporal (B=0.026, 95% CI: 0.016 to 0.036, r=0.779, p<0.001), and total (B=0.022, 95% CI: 0.014 to 0.031, r=0.803, p<0.001) gray matter, and with greater increase in total CSF (B=-0.560, 95% CI: -0.270 to -0.850, r=-0.722, p=0.001). Controls did not show significant associations between brain volume changes and GSH levels. GSH deficit during the first psychotic episode was related to greater loss of cortical GM two years later in patients with first-episode EOP, suggesting that oxidative damage may contribute to the progressive loss of cortical GM found in patients with first-episode psychosis.


Journal of Clinical Psychopharmacology | 2016

Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review

Saínza García; Mónica Martínez-Cengotitabengoa; Saioa López-Zurbano; Iñaki Zorrilla; Purificación López; Eduard Vieta; Ana González-Pinto

Abstract Antipsychotics are the drugs prescribed to treat psychotic disorders; however, patients often fail to adhere to their treatment, and this has a severe negative effect on prognosis in these kinds of illnesses. Among the wide range of risk factors for treatment nonadherence, this systematic review covers those that are most important from the point of view of clinicians and patients and proposes guidelines for addressing them. Analyzing 38 studies conducted in a total of 51,796 patients, including patients with schizophrenia spectrum disorders and bipolar disorder, we found that younger age, substance abuse, poor insight, cognitive impairments, low level of education, minority ethnicity, poor therapeutic alliance, experience of barriers to care, high intensity of delusional symptoms and suspiciousness, and low socioeconomic status are the main risk factors for medication nonadherence in both types of disorder. In the future, prospective studies should be conducted on the use of personalized patient-tailored treatments, taking into account risk factors that may affect each individual, to assess the ability of such approaches to improve adherence and hence prognosis in these patients.


Progress in Neuro-psychopharmacology & Biological Psychiatry | 2013

Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients.

Aitor Palomino; Ana González-Pinto; Mónica Martínez-Cengotitabengoa; Sonia Ruiz de Azúa; Susana Alberich; Fernando Mosquera; Carlos Matute

Previous studies have suggested that insulin-like growth factor-1 (IGF-1) is altered in schizophrenia. The objective of this study was to investigate whether plasma IGF-1 levels were altered at the onset of psychiatric disorders such as schizophrenia or bipolar disorder. We focused at the first psychotic episode (FPE) and during 1-year follow-up. We also studied if IGF-1 levels were related to clinical symptoms. 50 patients and 43 healthy controls matched by age, gender and educational level were selected from the Basque Country catchment area in Spain. Plasma IGF-1 levels were measured at FPE and 1 month, 6 months and one year later. Patient symptoms were assessed at the same disease stages using the Positive and Negative Symptoms Scale (PANSS), the Global Assessment of Functioning (GAF), the Hamilton Depression Rating Scale (HDRS21) and the Young Mania Rating Scale (YMRS). A statistically significant increase in the plasma levels of IGF-1 was found in the whole cohort of patients one month after FPE compared to matched controls (219.84 ng/ml vs 164.15 ng/ml; p=0.014), as well as in schizophrenia patients alone at that stage (237.60 ng/ml vs 171.60 ng/ml; p=0.039). In turn, negative symptoms in both groups of patients were positively correlated with IGF-1 levels both at FPE (β=0.521; p<0.001) and after 1 year (β=0.659; p=0.001), being patients diagnosed with schizophrenia the main contributors to this relationship. These results indicate that there is a significant change in the plasma levels of IGF-1 at the initial stages of schizophrenia but not in bipolar disorder, and suggest that IGF-1 could have role in the pathophysiology of negative symptoms.


Bipolar Disorders | 2012

Impact Of Sunlight on the Age Of Onset Of Bipolar Disorder

Michael Bauer; Tasha Glenn; Martin Alda; Ole A. Andreassen; Raffaella Ardau; Frank Bellivier; Michael Berk; Thomas Bjella; Letizia Bossini; Maria Del Zompo; Seetal Dodd; Andrea Fagiolini; Mark A. Frye; Ana González-Pinto; Chantal Henry; Flávio Kapczinski; Sebastian Kliwicki; Barbara König; Maurício Kunz; Beny Lafer; Carlos López-Jaramillo; Mirko Manchia; Wendy K. Marsh; Mónica Martínez-Cengotitabengoa; Ingrid Melle; Gunnar Morken; Rodrigo A. Munoz; Fabiano G. Nery; Claire O’Donovan; Andrea Pfennig

Bauer M, Glenn T, Alda M, Andreassen OA, Ardau R, Bellivier F, Berk M, Bjella TD, Bossini L, Del Zompo M, Dodd S, Fagiolini A, Frye MA, Gonzalez‐Pinto A, Henry C, Kapczinski F, Kliwicki S, König B, Kunz M, Lafer B, Lopez‐Jaramillo C, Manchia M, Marsh W, Martinez‐Cengotitabengoa M, Melle I, Morken G, Munoz R, Nery FG, O’Donovan C, Pfennig A, Quiroz D, Rasgon N, Reif A, Rybakowski J, Sagduyu K, Simhandl C, Torrent C, Vieta E, Zetin M, Whybrow PC. Impact of sunlight on the age of onset of bipolar disorder. Bipolar Disord 2012: 14: 654–663.


Schizophrenia Research | 2014

A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis

David Fraguas; Jessica Merchán-Naranjo; Ángel del Rey-Mejías; Josefina Castro-Fornieles; Ana González-Pinto; Marta Rapado-Castro; Laura Pina-Camacho; Covadonga M. Díaz-Caneja; Montserrat Graell; Soraya Otero; Inmaculada Baeza; Carmen Moreno; Mónica Martínez-Cengotitabengoa; Elisa Rodríguez-Toscano; Celso Arango; Mara Parellada

BACKGROUND The relationship between duration of untreated psychosis (DUP) and executive function (EF) in patients with first-episode psychosis (FEP) is controversial. We aim to assess the influence of DUP on changes in EF over a 2-year period in subjects with early-onset FEP (first psychotic symptom before age 18) and less than 6 months of positive symptoms. METHODS A total of 66 subjects were included in the study (19 females [28.8%], mean age 16.2 ± 1.6 years). The influence of DUP on changes in EF over the 2-year follow-up (expressed as a composite score of 5 cognitive abilities: attention, working memory, cognitive flexibility, response inhibition, and problem solving) was estimated using a multivariate linear regression model after removing the effect of intelligence quotient and controlling for age, gender, diagnosis, premorbid adjustment, severity of positive and negative symptoms at baseline, global functioning at baseline, and mean daily antipsychotic dosage during follow-up. RESULTS Mean DUP was 65.0 ± 6.9 days (95% confidence interval [CI], 51.2, 78.8). Median DUP was 47.5 days (range 2-180 days). Negative symptoms at baseline was the only variable significantly associated with EF at baseline (10.9% of explained variance [e.v. 10.9%], p=0.007). Only shorter DUP (e.v. 8.7%, p=0.013) and greater severity of baseline negative symptoms (e.v. 10.0%, p=0.008) were significantly associated with greater improvement in EF. CONCLUSIONS In early-onset FEP, shorter DUP was associated with greater improvement in EF over a 2-year follow-up period.


Journal of Affective Disorders | 2014

Relationship between sunlight and the age of onset of bipolar disorder: an international multisite study.

Michael Bauer; Tasha Glenn; Martin Alda; Ole A. Andreassen; Elias Angelopoulos; Raffaella Ardau; Christopher Baethge; Rita Bauer; Frank Bellivier; R.H. Belmaker; Michael Berk; Thomas Bjella; Letizia Bossini; Yuly Bersudsky; Eric Yat Wo Cheung; Jörn Conell; Maria Del Zompo; Seetal Dodd; Bruno Etain; Andrea Fagiolini; Mark A. Frye; Kostas N. Fountoulakis; Jade Garneau-Fournier; Ana González-Pinto; Hirohiko Harima; Stefanie Hassel; Chantal Henry; Apostolos Iacovides; Erkki Isometsä; Flávio Kapczinski

BACKGROUND The onset of bipolar disorder is influenced by the interaction of genetic and environmental factors. We previously found that a large increase in sunlight in springtime was associated with a lower age of onset. This study extends this analysis with more collection sites at diverse locations, and includes family history and polarity of first episode. METHODS Data from 4037 patients with bipolar I disorder were collected at 36 collection sites in 23 countries at latitudes spanning 3.2 north (N) to 63.4 N and 38.2 south (S) of the equator. The age of onset of the first episode, onset location, family history of mood disorders, and polarity of first episode were obtained retrospectively, from patient records and/or direct interview. Solar insolation data were obtained for the onset locations. RESULTS There was a large, significant inverse relationship between maximum monthly increase in solar insolation and age of onset, controlling for the country median age and the birth cohort. The effect was reduced by half if there was no family history. The maximum monthly increase in solar insolation occurred in springtime. The effect was one-third smaller for initial episodes of mania than depression. The largest maximum monthly increase in solar insolation occurred in northern latitudes such as Oslo, Norway, and warm and dry areas such as Los Angeles, California. LIMITATIONS Recall bias for onset and family history data. CONCLUSIONS A large springtime increase in sunlight may have an important influence on the onset of bipolar disorder, especially in those with a family history of mood disorders.


Psychiatry Research-neuroimaging | 2012

Adaptive response in the antioxidant defence system in the course and outcome in first-episode schizophrenia patients: A 12-months follow-up study

Fátima Ruiz-Litago; Jesús Seco; Enrique Echevarría; Mónica Martínez-Cengotitabengoa; Javier Gil; Jon Irazusta; Ana González-Pinto

Correlation of plasma antioxidant enzyme activity with the course and outcome in first-episode schizophrenia patients (n=49) was analyzed in order to assess the possible utility of peripheral markers of oxidative stress as prognostic factors. These markers were measured shortly after the onset of schizophrenia, and again 1, 6 and 12 months later. A decrease in catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and glutathione (GSH) levels and total antioxidant status (TAS), as well as an increase in thiobarbituric acid reactive substances (TBARS), were observed 1 month after (p<0.05). 6-Months later, there was a reduction in TAS, GSH, SOD and GPx, and a increase in TBARS (p<0.05), with a normalization of CAT levels, indicating a persistent alteration of the antioxidant system and the maintenance of oxidative stress. At 12-months, a considerable decrease was observed in TBARS. Additionally, while the level of GPx decreased (p<0.05) further, SOD and GSH levels and TAS were normalizing, indicating a partial regeneration of the antioxidant defence system. These results indicate the possible contribution of oxidative stress to the onset and pathophysiology of schizophrenia, suggesting the involvement of an adaptive response in the antioxidant defence system in the course and outcome in first-episode schizophrenia patients.

Collaboration


Dive into the Mónica Martínez-Cengotitabengoa's collaboration.

Top Co-Authors

Avatar

Ana González-Pinto

University of the Basque Country

View shared research outputs
Top Co-Authors

Avatar

A. González-Pinto

University of the Basque Country

View shared research outputs
Top Co-Authors

Avatar

Susana Alberich

University of the Basque Country

View shared research outputs
Top Co-Authors

Avatar

Itxaso González-Ortega

University of the Basque Country

View shared research outputs
Top Co-Authors

Avatar

Mara Parellada

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Iñaki Zorrilla

University of the Basque Country

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Juan C. Leza

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Amaia Ugarte

University of the Basque Country

View shared research outputs
Top Co-Authors

Avatar

Celso Arango

Complutense University of Madrid

View shared research outputs
Researchain Logo
Decentralizing Knowledge